The caspase family of proteases has previously been implicated in the biochemical cascade leading to apoptotic cell death. Recently caspase-3 was reported to be cleaved into its catalytically active subunits (17 and 13 kDa) following phytohemagglutinin ( Caspase-3-like protease-generated PARP and ␣-spectrin breakdown product formation was also reduced by Z-D-DCB. In addition, Jurkat T-cells costimulated with anti-CD3 plus anti-CD28 produced significant levels of IL-2 that were also blocked by these caspase inhibitors. Importantly, IL-2 was determined in cell culture supernatants, thus avoiding a cell lysis step that might have enabled activation of caspase-3 by granzyme B. Collectively, these data support the role of caspase-3-like protease activity in Jurkat T-cell activation and demonstrate that caspase-3 like activity is necessary for IL-2 release in PHA-activated and anti-CD3/anti-CD28 costimulated Jurkat T-cells.
INTRODUCTION
The participation of the caspase family (previously called the interleukin-1␤ converting enzyme family) of cysteine proteases in programmed cell death (apoptosis) is well established [3] [4] [5] [6] . Apoptosis is required for the development and maintenance of cells in many organ systems, including neuronal cells [7] [8] [9] , cardiac cells [10] , and immune cells [11] [12] [13] [14] [15] . In addition apoptosis has been implicated in many disease processes, such as Alzheimer's disease [16] , Huntingtons disease [17] , and amyotrophic lateral sclerosis [18] . However, two recent studies have shown that high levels of caspase-3-like activity can occur in the absence of apoptotic cell death [1, 19] . In the first study, Miossec and colleagues [1] showed that caspase-3-like activity occurred in PHA activated T-cells. In the second report [19] it was demonstrated that when epithelial cells terminally differentiate into enucleated lens fibers, caspase-3-like activity was markedly enhanced. These observations suggested that caspase-3-like proteases may not be exclusively death effector proteases but may indeed be involved in other cellular processes not accompanied by cell death. However, a recent report from Zapata and colleagues [2] claims that the caspase-3 activity previously described by Miossec et al. [1] was a methodological artifact related to the cell lysis buffer. Currently, the involvement of caspase-3-like protease activation in T-cell activation and other nonapoptotic events has yet to be established.
Several apoptotic challenges have been shown to activate caspase-3 from a 32-kDa pro-enzyme into 20- [20, 21] , 17-, and 13-kDa fragments [15, 22, 23] . The latter two form the active enzyme complex. Caspase-3 has a conserved pentapeptide active site QACXG (where X is R, Q, or G) common to the caspase family and a preference for proteins that contain a DXXD motif at P 4 -P 1 [23] [24] [25] . Activated caspase-3 can proteolytically cleave a number of intracellular, membrane, and nuclear proteins that are associated with apoptotic cell death [22, 26, 27] including poly(ADP-ribose) polymerase (PARP) [23, 28] , ␣-spectrin [29, 30] , sterol regulatory element binding proteins [31] , the 70-kDa protein component of the U1-ribonucleopro-tein [32] , and the catalytic subunit of DNA-dependent protein kinase [32] .
T-cell activation is initiated by the binding of foreign antigens to the T-cell receptor complex (TCR) [33] . Subsequent signal transduction events include the activation of protein tyrosine kinases (i.e., Fyn, Lck, and ZAP-70) [33] , PKC [34, 35] , and Ras-related G proteins [36] , which contribute to the expression of several cytokines including interleukin-2 (IL-2) [37, 38] . IL-2 is required for growth and differentiation of B-cells [39] and of T-cells [40] . In the present study we explored the physiological significance of caspase-3-like proteases in normal T-cell activation. First, we confirmed that caspase-3 processing occurs in activated T-cells using the preferred sample processing methodology of Zapata and colleagues [2] . Second, we demonstrated that caspase-3-like protease activation accompanies PHA stimulated and anti-CD3/anti-CD28 costimulated IL-2 release in the absence of cell death. Third, and importantly, we also show that caspase inhibitors (carbobenzoxy-Asp-CH 2 OC(O)-2,6-dichlorobenzene (Z-D-DCB) [41] and acetyl-aspartate-glutamatevaline-aspartate-CHO (Ac-DEVD-CHO)) can markedly attenuate IL-2 release in PHA-activated and anti-CD3/ anti-CD28 costimulated Jurkat T-cells. We conclude that caspase-3-like activity is necessary for IL-2 release in activated Jurkat T-cells. IL-2 immunoassay. Human IL-2 was detected using R&D Systems Quantikine Human IL-2 immunoassay detection kits (Minneapolis, MN). Supernatants were collected from Jurkat T-cell cultures at 6, 16, and 24 h post PHA administration.
METHODS

PHA challenge and anti-CD3/anti-CD28 costimulation of human
LDH measurement. Cell death was assessed in Jurkat T-cells by measuring the release of the cytosolic enzyme, lactate dehydrogenase (LDH) using a Cytotox kit 96 (Promega [Madison, WI]).
Protein extraction, SDS-PAGE, and Western blot methodology.
On completion of the experimental protocols, Jurkat T-cells were washed twice with TBS-EDTA (20 mM Tris-HCl, pH 7.4, 155 mM NaCl, and 1 mM EDTA). SDS-protein extractions of cell lysates were performed in the presence of protease inhibitors containing 2% SDS as previously described [44] . The extraction procedure was completed by precipitating the proteins with trichloroacetic acid and resolubilization of the pellet was achieved with 3 M Tris base. Protein determination of samples was performed using a modified Lowry assay and bovine serum albumin standards. Protein samples containing 5-15 g of protein were run on 4 -20% acrylamide gradient gels (Novex [San Diego, CA]) employing a Tris glycine running buffer. Following separation of proteins by SDS-PAGE, proteins were transferred onto a PVDF membrane using a Tris glycine buffer (48 mM Tris base, 39 mM glycine, and 10% MeOH, pH 8.3) and semi-dry electrotransferring unit (Bio-Rad) at 20 mV for 2 h. All lanes contained identical amounts of protein. To insure consistency of loading, gels were routinely stained with Coomassie blue dye. Triton X-100 protein extraction for assaying caspase-3-like activity. On completion of the experimental protocols, Jurkat T-cells were collected from 3 wells of a 12-well plate, placed in 15-ml centrifuge tubes, and washed twice with 5 ml of TBS-EDTA buffer by centrifugation for 5 min at 4°C. Cell pellets were resuspended and lysed in a buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM dithiothreitol (DTT), 5 mM EDTA, 5 mM EGTA, and 1% Triton X-100 for 60 min at 4°C. Cell lysates were then recovered after centrifugation and stored in 50% glycerol at Ϫ70°C. All cell lysates were assayed for protein concentration with a modified Lowry assay. Caspase-3-like and caspase-1-like proteolytic activities were assayed using the fluorometric peptide substrates Ac-DEVD-MCA or Ac-YVAD-MCA, respectively (where MCA represents 7-amido-4-methylcoumarin) (Bachem Bioscience, Inc. [King of Prussia, PA]). Cell lysates were added to a buffer (200 l) containing 100 M peptide substrate, 100 mM Hepes, 10% glycerol, 1 mM EDTA, 10 mM DTT, and 10 M of the general caspase inhibitor Z-D-DCB. Fluorescence (excitation 380 Ϯ 15 nm and emission 460 Ϯ 15 nm) was measured every 15 min up to 60 min with a Millipore Cytoflor 2300 fluorescence plate reader.
RESULTS
PHA stimulation of Jurkat T-cells results in the production of proteolytic activity suggestive of caspase-3-like proteolysis.
Protein extracts from PHA-stimulated Jurkat T-cells were collected at 0, 6, and 16 h and analyzed using SDS-PAGE and Western blotting methodology to establish the temporal profile for caspase-3-like protease activation, as well as the hydrolysis of preferred intracellular substrates of caspase-3. The Western blots were probed with antibodies against caspase-3, the nuclear enzyme PARP, and ␣-spectrin to detect the presence of lower molecu-lar weight break down products (BDPs) suggestive of caspase-3-like proteolysis. The production of the 17 and 13-kDa caspase-3 fragments was maximal at 16 h following PHA stimulation (Fig. 1A) . Anti-fas, an established inducer of apoptosis and caspase activation in T-cells [45] , also produced the active lower molecular weight caspase-3 fragments. The caspase-3 cleavage products detected following anti-fas treatment had molecular weights approximating those seen in PHAtreated Jurkat cultures (Fig. 1A) .
Cleavage of the parent PARP from a 110-kDa protein to an 85-kDa BDP characteristic of caspase-3-like protease cleavage was also detected in cell lysates at 16 h following PHA activation (Fig. 1B) . Anti-fas-treated Jurkat T-cells (at 6 h) expectedly produced the 85-kDa PARP BDP detected in PHA-treated cultures. Western blots on PHA-activated Jurkat T-cell protein extracts were also probed for the appearance of the caspase-3-generated 120-kDa ␣-spectrin BDP (Fig. 1C) . PHAactivated T-cells contained a 120-kDa fragment at 16 h post activation. Anti-fas apoptotic controls at 6 h post challenge contained the identical 120-kDa ␣-spectrin BDP detected in PHA-treated Jurkat T-cells. Immunoblots also revealed that the caspase inhibitor Z-D-DCB (50 M) significantly blocked caspase-3 processing (Fig. 1A) , PARP cleavage (Fig. 1B) , and the accumulation of the 120-kDa spectrin BDP (Fig. 1C) when Z-D-DCB was used as a Jurkat pretreatment.
To examine further the type of protease activity present in PHA-activated Jurkat T-cells, cell lysates were extracted for enzymatic assay. Two fluorogenic peptide substrates, Ac-DEVD-MCA and Ac-YVAD-MCA, were used to examine the activity of caspase-1-like and caspase-3-like proteases, respectively, in cell lysates (Fig. 2) . The activity units expressed in this assay are the average relative fluorescent units detected at 460 Ϯ 15 nm per g of protein for the given experimental conditions (n ϭ 3). Cleavage of Ac-DEVD-MCA was used to infer caspase-3-like activity because it is preferred over Ac-YVAD-MCA [25] : caspase-1 cleaves both substrates at a similar rate [23] . Ac-DEVD-MCA hydrolysis from cell lysates obtained from PHA-stimulated Jurkat T-cells demonstrated a slight but statistically significant increase in hydrolytic activity at 16 h (0.322 fluorescent units) and at 24 h (0.522 fluorescent units) compared with control (0.160 fluorescent units) (2.02-and 3.27-fold control, respectively) (Fig. 2) . Ac-DEVD-MCA hydrolysis at 6 h post PHA challenge in Jurkat T cells was comparable to that at 16 h but was not significant in comparison to untreated controls. PHA-stimulated Jurkat T-cells demonstrated nonsignificant (P Ͼ 0.05) levels of Ac-YVAD-MCA hydrolytic activity at all time points ex- amined in these studies (data not shown). The pan caspase inhibitor, Z-D-DCB (50 M), completely blocked Ac-DEVD-MCA hydrolysis at 16 h post PHA stimulation (0.70-fold increase compared with control). As expected, anti-fas-treated cell cultures demonstrated marked increases in Ac-DEVD-MCA hydrolysis at 3 h (2.231 fluorescent units; 13.97-fold control) and at 6 h (1.091 fluorescent units; 6.83-fold control) post PHA stimulation in comparison to untreated controls (Fig. 2) . Ac-YVAD-MCA hydrolysis was not significantly increased 6 and 16 h after anti-fas treatment (P Ͼ 0.05, data not shown).
Jurkat T-cell activation results in IL-2 release that is inhibited by the caspase inhibitors Z-D-DCB and Ac-DEVD-CHO.
Jurkat T-cells were pretreated with the pan caspase inhibitor Z-D-DCB and challenged with PHA to determine if caspase activation is necessary for IL-2 release following PHA-induced T-cell activation. Jurkat T-cells produced a marked increase in IL-2 release over untreated controls as early as 16 h (174.6 Ϯ 12.1 pg/ml; P Ͻ 0.001) and sustained increases in IL-2 release for at least 24 h (75.5 Ϯ 8.2 pg/ml; P Ͻ 0.05) following PHA administration (Fig. 3A) . Rolipram (Rol, 30 M), a selective PDE-4 inhibitor previously reported to inhibit IL-2 release [46] , significantly reduced IL-2 levels by 66% at 16 h (58.6 Ϯ 13.8 pg/ml vs 174.6 Ϯ 12.1 pg/ml; P Ͻ 0.001) and 51% at 24 h (37.0 Ϯ 3.0 pg/ml vs 75.5 Ϯ 8.2; P Ͻ 0.001) post PHA stimulation (Fig. 3A) . The pan caspase inhibitor, Z-D-DCB (Z-D, 50 M), also markedly attenuated IL-2 release at 16 h (93% reduction; 11.5 Ϯ 3.3 pg/ml vs 174.6 Ϯ 12.1 pg/ml; P Ͻ 0.001) and 24 h (57% reduction; 32.7 pg/ml Ϯ 3.3 vs 75.5 Ϯ 8.2 pg/ml; P Ͻ 0.001) following stimulation (Fig.  3A) . Anti-fas-treated Jurkat T-cells failed to induce a significant increase in IL-2 release at any time point examined following PHA challenge (P Ͼ 0.05) (Fig. 3A) .
LDH release was not enhanced in PHA-stimulated Jurkats at any time point evaluated (P Ͼ 0.05) (Fig.  3B) . As a control, anti-fas treatment of Jurkat T-cells did result in increased LDH release at 16 h (0.876 Ϯ 0.04 LDH units) and 24 h (1.344 Ϯ 0.06 LDH units) compared to untreated controls (0.204 Ϯ 0.01 and 0.227 Ϯ 0.00 LDH units, respectively). Cultures pretreated with Z-D-DCB plus PHA also did not exhibit an increase in LDH release (P Ͼ 0.05). Morphologically, PHA-treated cells were devoid of all apoptotic phenotypes as described previously [30, 43] (data not shown).
We further examined the Z-D-DCB concentrationdependent reduction of IL-2 release in PHA-activated Jurkat T-cells (Fig. 4A) . The dose-response effects of Z-D-DCB were determined at 16 h post PHA challenge because IL-2 release was greatest at this time point (Fig. 3A) . caspase inhibitor (Ac-DEVD-CHO, 100 M) which also markedly reduced IL-2 release at 16 h following PHA stimulation (71.1 Ϯ 2.2 vs 227.1 Ϯ 11.1 pg/ml, P Ͻ 0.01) (Fig. 4A) .
Next we extended our investigation utilizing another pathway of T-cell activation, namely, anti-CD3 plus anti-CD28 costimulation. IL-2 release was detected at 16 h following the costimulation of Jurkat T-cells with anti-CD3/anti-CD28 ( 
DISCUSSION
In this study we examined a possible role for caspase-3-like proteases in PHA or anti-CD28 plus anti-CD3 activated Jurkat T-cells. The data in this study confirm that caspase-3-like protease activity is present in activated T-cells as first described by Miossec and colleagues in peripheral blood mononuclear cells (PBMC) [1] . Our paper also represents the first evidence that caspase-3-like protease activation is necessary for IL-2 production in PHA-activated T-cells. Moreover, we observed caspase-3 processing to the active 17-and 13-kDa caspase-3 subunits (Fig. 1A) in   FIG. 4 . Z-D-DCB dose-related inhibition of PHA and anti-CD3/anti-CD28 induced IL-2 release in Jurkat T-cells. Supernatants were assayed for IL-2 by ELISA and were obtained from Jurkat T-cells cultured in the absence or presence of increasing concentrations of Z-D-DCB (5, 15, 50, and 100 M) or Ac-DEVD-CHO (100 M) for 16 h after challenge with PHA (A) or anti-CD3/anti-CD28 costimulation (B). The data shown are the averages of three experiments (mean Ϯ SEM). Tukey-HSD ANOVA was performed to determine group differences (P Ͻ 0.05). "*" indicates significance at P Ͻ 0.05, "**" indicates significance at P Ͻ 0.01, and "***" indicates significance at P Ͻ 0.001 in comparison to the IL-2 released from corresponding PHA-(A) or anti-CD3/anti-CD28 (B) treated cultures.
activated Jurkats, in contrast to the finding of Miossec and colleagues [1] , who did not detect caspase-3 processing in Jurkat T cells at 24 h following PHA stimulation. We also showed that the caspase-3 substrates PARP and ␣-spectrin are indeed proteolyzed in PHAactivated T-cells (Figs. 1A and 1B) . Importantly, the appearance of the active 17-kDa caspase-3 cleavage product (Fig. 1A) , the 85-kDa PARP cleavage product [23, 28] (Fig. 1B) , and the exclusive caspase-3-generated 120-kDa ␣-spectrin BDP [29, 30] (Fig. 1C) , in the absence of apoptotic cell death, suggests that caspase-3-like activation is involved in intracellular signaling following T-cell activation. In addition, cleavage of the fluorometric caspase-3-like substrate Ac-DEVD-MCA [23] was observed without Ac-YVAD-MCA hydrolysis (preferred caspase-1 substrate; Fig. 2 ) in lysates from PHA-activated Jurkat T-cells. Collectively, these findings support a role for caspase-3-like proteases in Jurkat T-cell activation.
Recently, questions have been raised as to the validity of caspase-3 processing and its upregulated activity in activated T-cells. A recent paper from Zapata et al. [2] suggests that previous evidence of caspase-3 processing and activation [1] was due to a sample-processing artifact. Specifically, Zapata et al. claim that when activated T-cells are lysed in the absence of SDS, resident granzyme B is released into the lysate and subsequently cleaves and activates caspase-3. These events were demonstrated even if samples were kept at 0 -4°C. The authors [2] then reported that when the lysis buffer contained Ն2% SDS, or when an alternate lysis buffer such as a RIPA buffer containing antigranzyme B was used, caspase-3 processing and subsequent activity were not detected. However, the lines of evidence supporting caspase-3 processing in Jurkat T-cell activation in our current study were obtained using a lysis buffer that contained 2% SDS. In addition, our protocol used a trichloroacetic acid protein extraction step that would further limit enzymatic activity during sample processing.
Significant enhancement of IL-2 release was detected following PHA activation in Jurkat T-cells, peaking at 16 h (Fig. 3A) . Caspase-3-like activity and IL-2 release were each significantly elevated at 16 and 24 h after PHA treatment (Fig. 2 vs Fig. 3A) . We demonstrated almost a complete blockade of IL-2 release 16 h following pretreatment with 50 M Z-D-DCB (Fig. 3A) , suggesting that caspase-3-like activity might be required for the expression of IL-2 protein and/or its subsequent release, since IL-2 is not processed before secretion [47] . The inhibition of IL-2 release by Z-D-DCB (Fig. 4) was dose dependent and occurred in the absence of any increase of LDH. The ability of Z-D-DCB to attenuate IL-2 release following T-cell activation was similar to that of rolipram, a selective PDE4 inhibitor previously reported to inhibit IL-2 release [46] . In addition, the blockade of IL-2 release by Z-D-DCB in PHA-activated Jurkat T-cells paralleled the retention of a less active caspase-3 form (20 kDa) and the blockade of the 85-kDa PARP [23, 28] and 120-kDa ␣-spectrin [29, 30] BDP formation generated by caspase-3-like proteases (Fig. 1) . This reduction of IL-2 is caspase-inhibition specific as another caspase-3 inhibitor (Ac-DEVD-CHO) [48] also markedly reduced IL-2 release following PHA stimulation (Fig. 4A) . Moreover, caspase-3-like protease dependent IL-2 release was not restricted to PHA-activated Jurkat T-cells because Jurkat T-cells costimulated by anti-CD3 and anti-CD28 yielded IL-2 release that was also attenuated by Z-D-DCB in a dose-dependent manner and Ac-DEVD-CHO (Fig. 4B) .
The finding that caspase-3 inhibitors can prevent IL-2 release in activated Jurkat T-cells is significant since sample preparation for measurement of IL-2 by ELISA does not involve cell lysis. That is, exposure to and possible activation of caspase-3 by granzyme B should not occur under these conditions. These data then independently support the role of a caspase-3-like protease during T-cell activation. However, since IL-2 is not directly activated by proteolytic cleavage [47] , the role of caspase-3 in the signal transduction pathway that leads to IL-2 release represents an enigma. Nevertheless, new findings in the literature support the participation of caspase-3-like proteases in T-cell activation. A recent paper has provided confirmatory data that caspase-3-like proteases participate in T-cell proliferation upon activation by mitogens and IL-2 [49] . Another paper has shown that mice deficient in FADD, an adaptor protein that was previously shown to be involved in caspase-mediated apoptotic cell death, have an unexpected impairment in T-cell activation [50] . Moreover, other recent studies have shown that several substrates of caspase-3, when cleaved, can increase their overall activity [51] . These substrates include members of the MAP kinase family [51, 52] and Ras-related G-proteins [50, 53] , both of which contain proteins that are necessary but not sufficient for IL-2 release following T-cell activation. Future studies are clearly needed to establish a role for caspase-3 in T-cell activation.
The finding of significant levels of caspase-3-like activity ( Figs. 1 and 2 ) associated with neither elevated LDH levels (Fig. 3B ) nor morphological correlates of apoptosis (data not shown) is in stark contrast to caspase-3-mediated apoptotic cell death observed in anti-fas-treated T-cells [45] (Fig. 3B) . The findings reported here suggest that Jurkat T-cells have alternative pathways for activating caspase-3 physiologically which do not result in apoptotic cell death. Levels of caspase-3-like protease-mediated cleavage products and the hydrolysis of Ac-DEVD-MCA following PHAstimulated Jurkat T-cells were much lower than that achieved with anti-fas. The low levels of caspase-3-like activation possibly contribute to the lack of LDH release in PHA-activated Jurkat T-cells. The reason that Miossec and colleagues [1] did not detect caspase-3-like activity in Jurkat T-cells treated with PHA, and we were consistently able to do so, is not precisely clear. However, one possibility is that Miossec et al., [1] did not detect caspase-3-like activity due to the different lengths of time required for caspase-3 activation in Jurkat T-cells and PBMC cells treated with PHA. That is, in our studies the time course of caspase-3 activation in Jurkat T-cells following PHA treatment suggests that the highest amounts of caspase-3 processing occurred at around 16 h post PHA challenge, which is before the earliest time point examined in the Miossec et al. study [1] . Thus, a T-cell line can potentially be used to examine the role of caspase-3-like proteases in T-cell activation.
In closing, we demonstrated with several lines of evidence that caspase-3-like protease activation does occur in activated Jurkat T-cells and that this activation parallels IL-2 release. Moreover, caspase inhibition significantly reduced IL-2 release in both PHAactivated and anti-CD3/anti-CD28 costimulated Jurkat T-cells, suggesting that IL-2 release is dependent on caspase-3-like activity. Importantly, the evidence for caspase-3-like protease activation in Jurkat T-cell activation in this study was obtained using the preferred methodologies of Zapata et al. [2] . The evidence that the increase of caspase-3-like activity can occur in activated T-cells in the absence of overt cell death necessitates a reclassification of caspase-3-like proteases from being exclusively death proteases to enzymes that may have several functions in different cellular processes. Most recently, a report by Zhang et al. [54] has shown that caspase-3 can process IL-16, a proinflammatory cytokine, into a more active form. Since a large number of proteins can potentially be cleaved by caspase-3-like proteases, future studies are needed to clarify the target substrates that contribute to IL-2 release following T-cell activation.
